allergic reaction symptoms to semaglutide Can Cause Skin Sensitivity? What Know Ozempic Eye Side Effects: Blepharitis,

Description

And it may be the most important one

Lokesh Gupta (CEO) Conrage Ideas Private Limited Second Floor, Apartment No.303, Plot No.40, Preeti Apartment, Mouza Ajni, C/O Ajay Nathuji Kesare, Surendra Nagar, Nagpur - 440015, Maharashtra, India

Key Takeaways Retatrutide is a first-in-class triple agonist targeting GLP-1, GIP, and glucagon receptors developed by Eli Lilly Phase 2 results: Up to 24.2% body weight loss at the highest dose (12 mg) over 48 weeks, published in the New England Journal of Medicine Phase 3 TRIUMPH trials: Ongoing across 5 indications including obesity, type 2 diabetes, and MASH (fatty liver disease)

Triple agonists with GLP1, GIP and glucagon Given the efficacy and benefits of the dual GLP-1/GIP RA tirzepatide and the dual GLP-1/glucagon RA, a triple agonist targeting all three receptors (GLP-1/GIP/glucagon) may result in superior WL and glycaemic control than dual agonists